IDMC Recommends Continuation of ELI-002 7P Trial in PDAC
Written by
Cancer Network
Published
0
comments
0
min
The independent data monitoring committee confirmed the favorable safety profile of ELI-002 7P for the treatment of PDAC in the phase 1/2 AMPLIFY-7P trial.